3.76  -0.24 (-6%)		12-31 19:00
Open: 4.08 High: 4.1 Volume: 8,196,718		Pre. Close: 4 Low: 3.76 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	19.01	1-year :	22.2
Resists	First :	16.28	Second :	19.01
Pivot price	9.98
Supports	First :	8.44	Second :	3.59
MAs	MA(5) :	13.57	MA(20) :	9.76
	MA(100) :	10.89	MA(250) :	10.8
MACD	MACD :	1	Signal :	0.1
%K %D	K(14,3) :	85.9	D(3) :	81.1
RSI	RSI(14): 65.6
52-week	High :	16.28	Low :	3.59

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ HCMA ] has closed below upper band by 15.5%. Bollinger Bands are 610.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 38 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	14.51 - 14.58	14.58 - 14.64
Low:	14.32 - 14.4	14.4 - 14.48
Close:	14.37 - 14.49	14.49 - 14.61

Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.

Mon, 15 Apr 2024
Chiasma Stock Shoots Up On Being Acquired By Amryt Pharma In All Stock Deal - AOL

Thu, 05 Aug 2021
Amryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total ... - GlobeNewswire

Wed, 05 May 2021
Chiasma Stock Shoots Up On Being Acquired By Amryt Pharma In All Stock Deal - Yahoo Finance

Wed, 05 May 2021
Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases - GlobeNewswire

Mon, 07 Dec 2020
Chiasma Trades At A Big Discount To Fair Value With Mycapssa On The Market (NASDAQ:CHMA-DEFUNCT-520065) - Seeking Alpha

Wed, 02 Dec 2020
Revisiting Chiasma (NASDAQ:CHMA-DEFUNCT-520065) - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	14 (M)
Shares Float	4 (M)
Held by Insiders	99.1 (%)
Held by Institutions	40 (%)
Shares Short	6 (K)
Shares Short P.Month	1 (K)

EPS	0.11
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.62
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-1.8 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-1 (M)
Levered Free Cash Flow	1 (M)

PE Ratio	120.83
PEG Ratio	0
Price to Book value	-23.78
Price to Sales	0
Price to Cash Flow	-167.23

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.